Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 27Burkitt Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Immunoglobulin Light-chain Amyloidosis 4Smoldering Multiple Myeloma 3Neoplasms 3Lung Neoplasms 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Breast Neoplasms 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Prostatic Neoplasms 1Plasmacytoma 1Myelodysplastic Syndromes 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 61Rituximab 50fludarabine 34Prednisone 33Doxorubicin 28Biopsy 26Vincristine 25Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 16Lenalidomide 16obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × dexamethasone acetate × 1 year × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡